MedTrace Logo

Hemostatic Endothelial Dysfunction in Patients With Peripheral Artery Disease

NCT04391374 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 167

Last updated 2023-05-03

No results posted yet for this study

Summary

The study is aimed at evaluating the role of the activity of the key hemostatic parameters of endothelial dysfunction (nitric oxide II (NO) metabolites, plasmin activator inhibitor-1 (PAI-1), von Willebrand factor (vWF), coagulation factor VIII (FVIII), soluble endothelial protein C receptors (sEPCR)) in the development of disease progression, thrombotic complications and restenosis in subjects with atherosclerotic peripheral artery disease.

Conditions

Interventions

PROCEDURE

an arterial reconstructive procedure

Sponsors & Collaborators

  • Ryazan State Medical University

    lead OTHER

Principal Investigators

  • Nina Mzhavanadze, MD, PhD · RyazSMU

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2023-02-23
Completion
2023-03-23

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391374 on ClinicalTrials.gov